← Leaderboards
Hanping Feng
University Of Maryland Baltimore
$19,880,798
Attributed
$28,695,395
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.7M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,695,395 · 11
By mechanism
R01$18,425,310 · 6
U19$7,185,508 · 2
UG3$2,091,549 · 1
K01$605,033 · 1
R56$387,995 · 1
Top collaborators
- Zhiyong Yang7 shared
- Saul R Tzipori6 shared
- Lijuan Yuan5 shared
- Feng Wei1 shared
- Yongrong Zhang1 shared
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Lijuan Yuan$3,888,254
- Raphael Simon$3,358,086
- Wilbur H. Chen$12,119,388
- Feng Wei$7,358,626
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionToxinClostridium DifficileIn VitroBaseLeadIn VivoResponseAntibodiesMorbidity - Disease RateFutureIntestinesImmuneEnteralMediatingDesignRecurrenceDiarrheaAntibioticsPreventionProductionVaccinesCellsAnimal Model
Grant awards (48)
Development of Oral Immunotherapy against Clostridioides difficile Transmission$511,553
R01 · FY2025 · AI
A novel oral immunotherapy for chronic visceral pain of irritable bowel syndrome$2,091,549
UG3 · FY2024 · NS
Preventing norovirus and Clostridium difficile gastroenteritis by engineered probiotic yeast Saccharomyces boulardii secreting multi-specific single-domain antibodies$621,331
R01 · FY2024 · AI · contact PI
Characterization of neutralizing antitoxins and epitopes in Clostridium difficile patients$386,250
R01 · FY2024 · AI · contact PI
Probiotic yeast secreting single-domain antibodies to prevent Clostridium difficile and Campylobacter jejuni disease$635,670
U19 · FY2023 · AI · contact PI
Preventing norovirus and Clostridium difficile gastroenteritis by engineered probiotic yeast Saccharomyces boulardii secreting multi-specific single-domain antibodies$611,307
R01 · FY2023 · AI · contact PI
Characterization of neutralizing antitoxins and epitopes in Clostridium difficile patients$386,250
R01 · FY2023 · AI · contact PI
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection$1,008,708
R01 · FY2022 · AI
Preventing norovirus and Clostridium difficile gastroenteritis by engineered probiotic yeast Saccharomyces boulardii secreting multi-specific single-domain antibodies$608,573
R01 · FY2022 · AI · contact PI
Probiotic yeast secreting single-domain antibodies to prevent Clostridium difficile and Campylobacter jejuni disease$418,645
U19 · FY2022 · AI · contact PI
Characterization of neutralizing antitoxins and epitopes in Clostridium difficile patients$386,250
R01 · FY2022 · AI · contact PI
Preventing norovirus and Clostridium difficile gastroenteritis by engineered probiotic yeast Saccharomyces boulardii secreting multi-specific single-domain antibodies$600,213
R01 · FY2021 · AI · contact PI
Probiotic yeast secreting single-domain antibodies to prevent Clostridium difficile and Campylobacter jejuni disease$512,533
U19 · FY2021 · AI · contact PI
Characterization of neutralizing antitoxins and epitopes in Clostridium difficile patients$386,250
R01 · FY2021 · AI · contact PI
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection$167,253
R01 · FY2021 · AI
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection$2,154,339
R01 · FY2020 · AI
Preventing norovirus and Clostridium difficile gastroenteritis by engineered probiotic yeast Saccharomyces boulardii secreting multi-specific single-domain antibodies$647,849
R01 · FY2020 · AI · contact PI
Probiotic yeast secreting single-domain antibodies to prevent Clostridium difficile and Campylobacter jejuni disease$498,984
U19 · FY2020 · AI · contact PI
Characterization of neutralizing antitoxins and epitopes in Clostridium difficile patients$386,250
R01 · FY2020 · AI · contact PI
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection$2,138,618
R01 · FY2019 · AI
Probiotic yeast secreting single-domain antibodies to prevent Clostridium difficile and Campylobacter jejuni disease$438,187
U19 · FY2019 · AI · contact PI
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection$1,170,960
R01 · FY2018 · AI
Novel Immunoprophylaxes against Clostridium difficile Infection$1,022,815
U19 · FY2018 · AI · contact PI
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection$1,460,626
R01 · FY2017 · AI
Novel Immunoprophylaxes against Clostridium difficile Infection$926,180
U19 · FY2017 · AI · contact PI
Novel Immunoprophylaxes against Clostridium difficile Infection$960,005
U19 · FY2016 · AI · contact PI
Novel Immunoprophylaxes against Clostridium difficile Infection$893,756
U19 · FY2015 · AI · contact PI
Novel Immunoprophylaxes against Clostridium difficile Infection$878,733
U19 · FY2014 · AI · contact PI
Development of Vaccines against Clostridium difficile Infection$631,430
R01 · FY2014 · AI · contact PI
Epithelium, dendritic cells, and Clostridium difficile associated colitis$315,327
R01 · FY2014 · DK · contact PI
Development of Vaccines against Clostridium difficile Infection$594,490
R01 · FY2013 · AI · contact PI
Toxemia and systemic disease in Clostridium difficile infection$387,995
R56 · FY2013 · AI · contact PI
Epithelium, dendritic cells, and Clostridium difficile associated colitis$304,291
R01 · FY2013 · DK · contact PI
Development of Vaccines against Clostridium difficile Infection$639,528
R01 · FY2012 · AI · contact PI
Epithelium, dendritic cells, and Clostridium difficile associated colitis$285,464
R01 · FY2012 · DK · contact PI
Development of Vaccines against Clostridium difficile Infection$309,454
R01 · FY2011 · AI · contact PI
Development of Vaccines against Clostridium difficile Infection$300,283
R01 · FY2011 · AI · contact PI
Epithelium, dendritic cells, and Clostridium difficile associated colitis$194,624
R01 · FY2011 · DK · contact PI
Epithelium, dendritic cells, and Clostridium difficile associated colitis$138,572
R01 · FY2011 · DK · contact PI
The role of dendritic cells in T cell immunity to Cryptosporidium$78,638
K01 · FY2011 · DK · contact PI
Development of Vaccines against Clostridium difficile Infection$663,948
R01 · FY2010 · AI · contact PI
Epithelium, dendritic cells, and Clostridium difficile associated colitis$415,319
R01 · FY2010 · DK · contact PI
The role of dendritic cells in T cell immunity to Cryptosporidium$100,896
K01 · FY2010 · DK · contact PI
The role of dendritic cells in T cell immunity to Cryptosporidium$126,338
K01 · FY2009 · DK · contact PI
The role of dendritic cells in T cell immunity to Cryptosporidium$54,000
K01 · FY2009 · DK · contact PI
The role of dendritic cells in T cell immunity to Cryptosporidium$1,080
K01 · FY2009 · DK · contact PI
The role of dendritic cells in T cell immunity to Cryptosporidium$123,445
K01 · FY2008 · DK · contact PI
The role of dendritic cells in T cell immunity to Cryptosporidium$120,636
K01 · FY2007 · DK · contact PI